论文部分内容阅读
目的分析替吉奥与5-氟尿嘧啶联合奥沙利铂治疗晚期胃癌的临床疗效及安全性。方法选取2011年1月至2014年7月间收治的90例晚期胃癌患者,采取随机数字表法分为对照组和试验组,每组45例。对照组给予5-氟尿嘧啶、奥沙利铂及亚叶酸钙治疗,试验组给予替吉奥联合奥沙利铂治疗,比较两组患者的临床疗效及不良反应。结果试验组患者的有效率和临床获益率分别为44.4%和91.1%,对照组分别为31.1%和75.6%,差异均有统计学意义(均P<0.05)。试验组与对照组在血细胞减少、血小板减少、恶心呕吐、贫血、外周神经毒性、腹泻及口腔黏膜炎方面差异均有统计学意义(均P<0.05)。结论采用替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效较为确切,不良反应较少,安全性较高,值得推广。
Objective To analyze the clinical efficacy and safety of tegaserod combined with 5-fluorouracil and oxaliplatin in the treatment of advanced gastric cancer. Methods Ninety patients with advanced gastric cancer who were admitted between January 2011 and July 2014 were randomly divided into control group and experimental group with 45 cases in each group. The control group was treated with 5-Fluorouracil, oxaliplatin and leucovorin, and the experimental group was treated with tioguanide plus oxaliplatin. The clinical efficacy and adverse reactions of the two groups were compared. Results The effective rate and clinical benefit rate of the trial group were 44.4% and 91.1%, respectively, which were respectively 31.1% and 75.6% in the control group (all P <0.05). There was significant difference between the experimental group and the control group in cytopenia, thrombocytopenia, nausea and vomiting, anemia, peripheral neurotoxicity, diarrhea and oral mucositis (all P <0.05). Conclusion The clinical efficacy of TEGO combined with oxaliplatin in the treatment of advanced gastric cancer is relatively accurate, with fewer adverse reactions and higher safety. It is worth promoting.